COFCOL COFCOL COFCOL COLD FREE DENORAL CONTAC-650 SPANSULA JUMSOL TRIAD COLD TRICOS TRICOS SINUTAB PECTUS FLUEZE FLUEZE FLUEZE FLUEZE FLUEZE COLDENE COLDENE COLDENE DAMSY HYDRYLLIN ANTI FLU HYDRYLLIN ANTI FLU HYDRYLLIN ANTI FLU RHINOTUSSAL TRICLOD TRICLOD DAMSY-P

Dose: 25 to 50 mg
Single Dose: 38 (37.5)
Frequency: 4 hourly
Route: PO
Instructions:

. It is of Synthetic origin and belongs to Amine. It belongs to Alpha adrenergic agonist pharmacological group on the basis of mechanism of action and also classified in CNS Stimulant and Decongestant pharmacological group.The Molecular Weight of Phenylpropanolamine (HCl) is 187.70. It is weakly acidic drug, 2.60% solution of the drug is isotonic and Its pKa is 9.4.

Phenylpropanolamine (HCl) is contraindicated in conditions like Glucoma,Hypertension,Hyperthyroidism,Prostatic hypertrophy,Intestinal obstruction.

Phenylpropanolamine (HCl) produces potentially life-threatening effects which include Hypertension. which are responsible for the discontinuation of Phenylpropanolamine (HCl) therapy.The signs and symptoms that are produced after the acute overdosage of Phenylpropanolamine (HCl) include Epileptic seizures, Hallucinations, Psychosis.The symptomatic adverse reactions produced by Phenylpropanolamine (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Palpitation, Termors, Chest tightness.

Phenylpropanolamine (HCl) is primarily indicated in conditions like Appetite suppresser, Cold, Congestion, Cough, Urinary incontinence.

Phenylpropanolamine (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAcebutololAtropine (Sulphate)Bromocriptine (Mesylate)Risk of toxicity when Bromocriptine given wih Phenylpropanolamine.MajorDebrisoquine (Sulphate)Doxepin (HCl)EphedrineThere is an increase in blood pressure and heart rate if this combination is used.ModerateThis combination is used cautiously and should monitor pulse and blood pressure.FurazolidoneCoadministration results hypertension and hyperpyrexia by sympathomimetic effect due to increase norepinephrine storage in neurons and increased release of catecholamine.MajorCoadministration should not be given if necessary then 14 days gap should be given during the initiation of other therapy.GuanethidineIndomethacinCoadministration of these agents causes increased sensitivity to sympathomimetic-induced blood pressure by inhibiting prostaglandin synthesis results in severe hypertension.ModerateClosely monitor for blood pressure of patient.LinezolidLisurideMoclobemideSibutramineThioridazine (HCl)Thioridazine antagonize the pharmacological effects of phenylpropanolamine. Conversely, phenylpropanolamine decreases the neuroleptic efficacy of thioridazine.ModerateCoadministration is considered contraindicated. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab, Cap Store at room temperature. Protect from Sunlight.

Use topical decongestant (phenylpropanolamine) only in acute conditions, not longer than 3 to 5 days. It should be used sparingly in all patients, especially in infants, children and in cardiac patients. Avoid continuous use for longer than 3 months.